Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AML

Novartis day

Novartis drug works in secondary progressive MS

Orally-active siponimod reduces risk of disability progression

- PMLiVE

AbbVie’s venetoclax set for early access in UK

Drug for CLL patients included in EAMS by MHRA

- PMLiVE

Lupus trial hailed as a success despite patient deaths

Phase IIb trial of Aurinia Pharmaceuticals’ voclosporin met its objective

Biogen Idec building

Biogen buys into Ionis’ nusinersen after positive phase III trial

Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 

- PMLiVE

Controversial new CDF promises “clearer, faster decision-making”

However, pharma companies and charities remain concerned over pricing and access

- PMLiVE

Tau protein drug fails late-stage trial

Alzheimer’s disease therapy only showed benefit in patients with no existing treatments

Boehringer Ingelheim headquarters

Boehringer stops Gilotrif head and neck cancer trials

Trial data suggests the drug is “highly unlikely” to prolong patients’ remission

Roche Basel Switzerland

Roche says Tecentriq “off to a good start”

Bladder cancer therapy drug seems set for rapid growth

Roche Basel Switzerland

Roche’s Gazyvaro flunks trial in non-Hodgkin’s lymphoma

Failed to improve progression-free survival when compared with its MabThera/Rituxan therapy

- PMLiVE

Novartis gets FDA panel backing for biosimilar Enbrel

However Amgen claims patent protection for the psoriatic arthritis therapy is valid until 2029

EU flag

European pharma ‘to grow 3.2% per year by 2022’

Forecast predicts AbbVie’s Humira will be knocked off the top spot

EU flag

EC approves Bial’s Parkinson’s disease therapy

Ongentys will be given a phase roll-out in 2016 and 2017

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links